Home » Stocks » FOLD

Amicus Therapeutics, Inc. (FOLD)

Stock Price: $21.85 USD 0.02 (0.07%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 5.61B
Revenue (ttm) 245.61M
Net Income (ttm) -295.18M
Shares Out 259.16M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $21.85
Previous Close $21.84
Change ($) 0.02
Change (%) 0.07%
Day's Open 21.90
Day's Range 21.08 - 22.18
Day's Volume 5,762,334
52-Week Range 6.63 - 24.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual...

Zacks Investment Research - 4 weeks ago

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FATE, RARE, XLRN
Benzinga - 1 month ago

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (...

Other stocks mentioned: SRPT
Zacks Investment Research - 1 month ago

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel m...

Zacks Investment Research - 1 month ago

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 month ago

Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.

GlobeNewsWire - 1 month ago

On Track for Completing the BLA Submission in 1H2021

Schaeffers Research - 1 month ago

The shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)  are up 1.3% at $22.69 at last check, after hitting a Nov. 18, all-time-high of $23.19.

GlobeNewsWire - 1 month ago

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at th...

Zacks Investment Research - 2 months ago

Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.

Seeking Alpha - 2 months ago

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10.00% and 3.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 2 months ago

CRANBURY, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suis...

Zacks Investment Research - 2 months ago

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

CRANBURY, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, November 5...

Zacks Investment Research - 3 months ago

Choosing breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy promises superlative returns.

Other stocks mentioned: AUG, GRBK, TRUE
GlobeNewsWire - 3 months ago

Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease Data Continue to Support Meaningful Effect on Motor and Language Function in...

Seeking Alpha - 3 months ago

Amicus is making progress on all fronts and the progress is not fully reflected in the company's valuation.

GlobeNewsWire - 3 months ago

Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in Oc...

Zacks Investment Research - 4 months ago

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 4 months ago

CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentat...

Seeking Alpha - 5 months ago

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

Zacks Investment Research - 5 months ago

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...

Benzinga - 5 months ago

Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of  $250M-$260M

Zacks Investment Research - 5 months ago

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Other stocks mentioned: HALO, ICPT, NVAX, RETA
GlobeNewsWire - 5 months ago

CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10,...

PRNewsWire - 5 months ago

INDIANAPOLIS, July 22, 2020 /PRNewswire/ -- The National Police Association (NPA) has filed a friend of the court brief asking the U.S. District Court for the District of Oregon to rule agains...

GlobeNewsWire - 6 months ago

$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings

Zacks Investment Research - 6 months ago

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Seeking Alpha - 7 months ago

Amicus Therapeutics: 2 Potential Blockbusters Make This Stock Worth Considering

Zacks Investment Research - 7 months ago

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Forbes - 8 months ago

Whether or not one agrees with DOJ’s call to drop its charges against former National Security Advisor Michael Flynn, there should be widespread agreement that Judge Emmet Sullivan has veered ...

InvestorPlace - 8 months ago

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

Other stocks mentioned: ARGX, ASND, AXSM, IOVA, NTRA, UTHR
Seeking Alpha - 8 months ago

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.00% and 5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 8 months ago

CRANBURY, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel ...

GlobeNewsWire - 8 months ago

CRANBURY, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel ...

Zacks Investment Research - 9 months ago

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 9 months ago

3 Covid-19 Proof Biotech Stocks

Other stocks mentioned: ALXN, EXEL
GlobeNewsWire - 9 months ago

CRANBURY, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering n...

The Motley Fool - 9 months ago

These five biotech stocks could post life-changing gains for early-bird investors.

Other stocks mentioned: BCYC, CPRX, INO, NVAX
The Motley Fool - 10 months ago

Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.

Other stocks mentioned: AMRN, CRSP
The Motley Fool - 10 months ago

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCEL, BCYC, BMY, CPRX, CRNX, GWPH, OGI, PFE, RCUS, SRPT
Zacks Investment Research - 10 months ago

Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.

Seeking Alpha - 10 months ago

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -34.62% and 2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 10 months ago

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About FOLD

Amicus Therapeutics, a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 an... [Read more...]

Industry
Biotechnology
IPO Date
May 31, 2007
CEO
John Crowley
Employees
584
Stock Exchange
NASDAQ
Ticker Symbol
FOLD
Full Company Profile

Financial Performance

In 2019, FOLD's revenue was $182.24 million, an increase of 99.72% compared to the previous year's $91.25 million. Losses were -$356.39 million, 2.12% more than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is 24.81, which is an increase of 13.55% from the latest price.

Price Target
$24.81
(13.55% upside)
Analyst Consensus: Buy